Beating Cancer by Targeting
MYC Cancer Gene and Immunity
MYCimmune is an international cancer research and innovation collaborative, which strives to advance clinically viable MYC oncogene-directed therapeutic concepts to early phase clinical testing. Our aim is to target critical MYC pathways with indirect and synthetic lethal strategies to trigger such cancer cell death that awakens anti-cancer immunity. This approach allows flexible design of combination treatments, including MYC-directed drugs and optimized immunotherapies for effective, durable and safe therapeutics across diverse cancer types.
Initiative to advance clinically viable MYC oncogene-directed therapeutic concepts to early phase clinical testing.